ECG-AI for Pulmonary Hypertension (PH)

About Anumana

Anumana is a private, commercial-stage AI diagnostics company that has successfully secured FDA clearance for its first algorithm detecting pulmonary hypertension, alongside a previously cleared algorithm for low ejection fraction. Its core strength lies in a proprietary AI platform trained on a massive, longitudinal dataset of over 22 million patient records, allowing it to extract novel clinical insights from standard ECGs. The company emphasizes seamless EHR integration and workflow compatibility to drive clinical adoption. With a growing pipeline of cardiac-focused algorithms and strong academic validation, Anumana is positioned as a leader in AI-enhanced cardiovascular diagnostics.

Therapeutic Areas